Notice of Award

Award# 6 NU50CK000546-02-09

FAIN# NU50CK000546

Federal Award Date: 05/12/2021

Recipient Information

1. Recipient Name

Missouri Department of Health 920 Wildwood Dr Jefferson City, MO 65109-5796 [NO DATA]

- 2. Congressional District of Recipient
- 3. Payment System Identifier (ID)
- 4. Employer Identification Number (EIN)
- 5. Data Universal Numbering System (DUNS)
- 6. Recipient's Unique Entity Identifier
- 7. Project Director or Principal Investigator

Mrs. Cheryl L Kerr Public Health Program Supervisor cheryl.kerr@health.mo.gov 5737516476

8. Authorized Official

Mrs. Marcia Mahanev Director, Division of Admnistration marcia.mahaney@health.mo.gov 573-751-6014

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Kim McDowell

Grant Management Specialist qpx9@cdc.gov

404-498-4105

10.Program Official Contact Information

Angelica O'Connor apw1@cdc.gov 404-639-7379

Federal Award Information

11. Award Number

6 NU50CK000546-02-09

12. Unique Federal Award Identification Number (FAIN) NU50CK000546

13. Statutory Authority

301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

14. Federal Award Project Title

CK19-1904 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)

15. Assistance Listing Number

16. Assistance Listing Program Title

Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)

17. Award Action Type

Supplement

18. Is the Award R&D?

Summary Federal Award Financial Information

19. Budget Period Start Date 08/01/2020 - End Date 07/31/2021

20. Total Amount of Federal Funds Obligated by this Action \$4,414,252.00 20a. Direct Cost Amount \$4,414,252.00 20b. Indirect Cost Amount \$0.00 21. Authorized Carryover \$0.00

22. Offset 23. Total Amount of Federal Funds Obligated this budget period \$541,674,395.00

24. Total Approved Cost Sharing or Matching, where applicable

25. Total Federal and Non-Federal Approved this Budget Period \$546,088,647.00

26. Project Period Start Date 08/01/2019 - End Date 07/31/2024

27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period

Not Available

\$0.00

\$0.00

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Freda Johnson

Grants Management Officer

30. Remarks

Notice of Award

Award# 6 NU50CK000546-02-09 FAIN# NU50CK000546

Federal Award Date: 05/12/2021

Recipient Information

Recipient Name

Missouri Department of Health 920 Wildwood Dr Jefferson City, MO 65109-5796 [NO DATA]

Congressional District of Recipient

Payment Account Number and Type

Employer Identification Number (EIN) Data

Universal Numbering System (DUNS)

878092600

Recipient's Unique Entity Identifier

Not Available

31. Assistance Type

Cooperative Agreement

32. Type of Award

Demonstration

33. Approved Budget (Excludes Direct Assistance)					
I. Financial Assistance from the Federal Awarding Agency Only					
II. Total project costs including grant funds and all other financial participation					
a. Salaries and Wages	\$13,348,140.00				
b. Fringe Benefits	\$8,005,145.00				
c. TotalPersonnelCosts	\$21,353,285.00				
d. Equipment	\$9,760,236.00				
e. Supplies	\$15,157,828.00				
f. Travel	\$291,696.00				
g. Construction	\$0.00				
h. Other	\$222,001,028.00				
i. Contractual	\$273,228,468.00				
j. TOTAL DIRECT COSTS	\$541,792,541.00				
k. INDIRECT COSTS	\$4,296,106.00				
1. TOTAL APPROVED BUDGET	\$546,088,647.00				
m. Federal Share	\$546,088,647.00				
n. Non-Federal Share	\$0.00				

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390GF6	19NU50CK000546PHL2C4	CK	41 51	\$142,473 00	75-X-0140
1-9390H08	19NU50CK000546AMD2C6	CK	41 51	\$4,271,779 00	75-X-0943



Award# 6 NU50CK000546-02-09 FAIN# NU50CK000546

Federal Award Date: 05/12/2021

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

Missouri Department of Health

6 NU50CK000546-02-09

1. Revised Terms and Conditions - Supp Funding

ADDITIONAL AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at

https://www.cdc.gov/grants/federalregulationspolicies/index.html, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CK19-1904, entitled *Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases(ELC)*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NOA).

Supplemental Component Funding: Additional funding in the amount \$4,414,252 is approved for the Year 02 budget period, which is August 1, 2020 through July 31, 2021, this award. The availability of funds is shown below.

COVID Funded Component	Amount	End of Funding Availability	Document Number in PMS
Project E: AMD Sequencing & Analytics	\$4,271,779	July 31, 2024	AMD2C6
Strengthening PHL Preparedness	\$142,473	July 31, 2022	PHL2C4

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); the Consolidated Appropriations Act and the Coronavirus Response and Relief Supplement Appropriations Act, 2021 (P.L. 116-260) and/or the American Rescue Plan of 2021 [P.L. 117-2] agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS—CoV—2 or to diagnose a possible case of COVID—19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited

to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

To achieve the public health objectives of ensuring the health, safety, and welfare of all Americans, Recipient must distribute or administer vaccine without discriminating on non-public-health grounds within a prioritized group.

Unallowable Costs:

- 1. Research
- 2. Clinical care
- 3. Publicity and propaganda (lobbying):
- 4. Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - b. the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body o See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
 - https://www.cdc.gov/grants/documents/AntiLobbying_Restrictions_for_CDC_Grantee s_July_2012.pdf
- All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

COVID-19 Funding Budget Revision Requirement: The recipient must submit a revised budget with a narrative justification within 90 days of receipt of the Notice of Award. If the date falls on a weekend or holiday, the submission will be due the following business day. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Awarding Agency Contact Information section on the first page before the due date.

REPORTING REQUIREMENTS

The following is a summary of the reporting requirements for the AMD Sequencing & Analytics.

- Within five (5) business days of receipt of this guidance, the Authorized Official is required to acknowledge receipt of this guidance by submitting a Grant Note in GrantSolutions.
- 2. Quarterly progress reports on milestones in approved workplans via REDCap.
- 3. Monthly fiscal reports (beginning 30 days after NOAs are issued).

- 4. Performance measure data.
- CDC may require recipients to develop annual progress reports (APRs). CDC will provide APR guidance and optional templates should they be required.

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services Kim McDowell, Grants Management Specialist Centers for Disease Control and Prevention Branch 1

2939 Flowers Road, MS-TV-2 Atlanta, GA 30341

Email: gpx9@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services Office of the Inspector General ATTN: Mandatory Grant Disclosures, Intake Coordinator 3301Independence Avenue, SW Cohen Building, Room 5527 Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC

20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of **Page 2** of the Notice of Award must be known to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.